Founded in 2014 with $40m in the bank, Therachon AG is developing TA-46 for achondroplasia, a molecule that CEO Luca Santarelli said the company evolved from an "academic prototype," created by founder Elvire Gouze, into what Santarelli hopes will be a solid industrial program, ultimately meeting the high unmet need for those suffering from genetic dwarfism.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?